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Abstract
Background: 5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the
most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and convenience
of administration facilitate use, however clinical resistance is a major limitation. Investigation has
failed to fully explain the molecular mechanisms of resistance and no clinically useful predictive
biomarkers for 5FU resistance have been identified. We investigated the molecular mechanisms of
clinical 5FU resistance in colorectal adenocarcinoma patients in a prospective biomarker discovery
project utilising gene expression profiling. The aim was to identify novel 5FU resistance mechanisms
and qualify these as candidate biomarkers and therapeutic targets.
Methods: Putative treatment specific gene expression changes were identified in a transcriptomics
study of rectal adenocarcinomas, biopsied and profiled before and after pre-operative short-course
radiotherapy or 5FU based chemo-radiotherapy, using microarrays. Tumour from untreated
controls at diagnosis and resection identified treatment-independent gene expression changes.
Candidate 5FU chemo-resistant genes were identified by comparison of gene expression data sets
from these clinical specimens with gene expression signatures from our previous studies of
colorectal cancer cell lines, where parental and daughter lines resistant to 5FU were compared. A
colorectal adenocarcinoma tissue microarray (n = 234, resected tumours) was used as an
independent set to qualify candidates thus identified.
Results: APRIL/TNFSF13 mRNA was significantly upregulated following 5FU based concurrent
chemo-radiotherapy and in 5FU resistant colorectal adenocarcinoma cell lines but not in
radiotherapy alone treated colorectal adenocarcinomas. Consistent withAPRIL's known function
as an autocrine or paracrine secreted molecule, stromal but not tumour cell protein expression by
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immunohistochemistry was correlated with poor prognosis (p = 0.019) in the independent set.
Stratified analysis revealed that protein expression of APRIL in the tumour stroma is associated
with survival in adjuvant 5FU treated patients only (n = 103, p < 0.001), and is independently
predictive of lack of clinical benefit from adjuvant 5FU [HR 6.25 (95%CI 1.48-26.32), p = 0.013].
Conclusions: A combined investigative model, analysing the transcriptional response in clinical
tumour specimens and cancers cell lines, has identified APRIL, a novel chemo-resistance biomarker
with independent predictive impact in 5FU-treated CRC patients, that may represent a target for
novel therapeutics.
Background
Significant progress has been made recently in the sys-
temic treatment of colorectal adnocarcinoma (CRC).
There are currently 8 agents licensed for use in the US and
Europe 5-fluorouracil (5FU), floxuridine, capecitabine,
irinotecan, oxaliplatin, cetuximab, panitumumab and
bevacizumab [1]. Combination therapy is the standard of
care for both early and advanced disease [1]. 5FU, or an
oral analogue capecitabine, is a component of the major-
ity of combination regimens and the low toxicity, ease
and convenience of administration, favour its clinical use.
However, a modest response rate due to clinical resistance
to 5FU is a major limitation. Older studies with 5FU mon-
otherapy demonstrate that the majority of CRC patients
treated will not benefit from 5FU, for example the objec-
tive response rate to 5FU or capecitabine monotherapy in
advanced CRC is 20% [1].
Identification of the clinically important mechanisms of
resistance to 5FU would allow better selection of patients
for 5FU therapy and the rationale design of targeted ther-
apeutics to overcome resistance, and thus increase the
proportion of patients deriving benefit from 5FU. A pre-
dictive biomarker for clinical 5FU resistance would clearly
be useful, but progress has been limited in this area and
investigation has thus far failed to fully explain the molec-
ular mechanisms that areimportant for clinical 5FU resist-
ance [2-4]. Preclinical and clinical studies have mainly
focussed upon molecules concerned with 5FU metabo-
lism (Dihydropyrimidine dehydrogenase (DPD), Thymi-
dine phosphorylase (TP)) or Thymidylate Synthase (TS),
a well characterised 5FU target [3,4]. Clinical studies in
colorectal cancer, assessing these molecules by a variety of
techniques (IHC, RT-PCR, ELISA, genotyping), while
demonstrating correlation between benefit (such as
response and survival) from 5FU or capecitabine, have so
far failed either to demonstrate genuine clinical utility as
predictive biomarkers or produce useful targeted agents
[3]. Overall, given the widespread clinical use of 5FU or its
oral formulations, there is still a need for novel discovery
approaches in this area.
The global perspective provided by gene expression profil-
ing has provided novel insights into the molecular mech-
anisms of clinical response to therapy in human cancers
[5], although few studies have specifically addressed clin-
ical therapy response in colorectal adenocarcinomas [6-
10] and only 1 has analysed serial biopsies before and
after treatment [8]. This report describes our prospectively
designed discovery study, Aberdeen Microarray in Rectal
Cancer Study-1 (AMRECS1) using a combined approach,
identifying candidate molecules from clinical specimens
and comparing them with our 5FU chemo-resistance data
from cell line model systems [11]. We aimed to identify
novel mechanisms of resistance to 5-fluorouracil (5FU)
that are clinically relevant in CRC patients. Tumour biop-
sies were collected before and after pre-operative therapy
in rectal cancer patients following staging and stratifica-
tion with magnetic resonance imaging (MRI), to identify
gene expression changes that occur following either 'short
course' radiotherapy (SCRT) or 5FU-based concurrent
chemo-radiotherapy (CRT). Gene expression profiles
from these matched clinical specimens were compared
with profiles generated from colorectal adenocarcinoma
cell lines, both sensitive parental and derived daughter
cell lines with increasing resistance to 5FU. Data is pre-
sented for the validation of one potential novel clinical
5FU resistance candidate APRIL/TNFSF13 in an independ-
ent set of 234 patients with colorectal cancer.
Methods
Patients, Follow up and Treatment
The study was approved by the North of Scotland
Research Ethics Committee. Patients provided informed
consent in accordance with the regulations and instruc-
tions of the North of Scotland Research Ethics Committee
for study participation, including use and publication of
results. Full clinicopathological details are provided in
table 1 and 2 and in Additional File 1. Patients were
selected for either SCRT or CRT based upon MRI staging
features [12]. All the radiotherapy was CT planned, using
a 3 field technique (posterior and two lateral fields), mul-
tileaf collimation and with patients having a full bladder
during the radiotherapy. Surgery was performed either the
following week, for SCRT patients, or 6 to 8 weeks after
completion of chemo-radiotherapy.
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Gene expression profiling
Tumour biopsies were collected at the time of endoscopic
diagnosis of rectal adenocarcinoma and placed immedi-
ately into RNAlater (800 μl) (Ambion, Austin, Texas).
Tumour biopsies collected at time of curative surgical
resection were placed immediately into normal saline and
a pathologist provided a representative tumour biopsy,
which was placed immediately into RNAlater within 30
minutes (800 μl). Tissues were stored in RNALater at 4°C
overnight (16-18 hours), then washed in 500 μl ice cold
RNase free PBS (Ambion, Austin, TX) and snap frozen in
liquid nitrogen. Long-term storage of tissues was at -80°C.
Before RNA extraction, histological diagnosis and features
were confirmed by frozen section histology. Extraction
and purification of total RNA was performed using TRI-
ZOL reagent (Invitrogen, Carlsbad, CA) and RNeasy
Microkits (Qiagen, Venlo, The Netherlands), according to
the manufacturer's instructions. Quantification of total
RNA was performed by spectrophometry (260/280 ratio
1.9 to 2.2 for all samples). Quality of total RNA and cRNA
was assessed using a BioAnalyser 2100 (Agilent technolo-
gies, Palo Alto, CA). Target preparation for the Affymetrix
Genechips™ was according to manufacturer's instructions
(Affymetrix, Santa Clara, CA). Specifically, 4 μg of total
RNA was used for reverse transcription and synthesis and
amplification of biotin labelled cRNA using the One cycle
target labelling and control reagents. Clean-up of biotin-
cRNA was performed with RNeasy Minikits (Qiagen,
Venlo, The Netherlands). Fragmentation was performed
using 20 μg of biotin-labelled cRNA. A hybridisation
cocktail was prepared from 15 μg which was first hybrid-
ised to Test 3 GeneChips™ to assess sample quality
(GAPDH 3':5' < 3 and Actin 3': 5' < 3) and then to
HGU133 Plus2.0 GeneChips™ (10 μg) for gene expression
analysis. Procedures for hybridisation, washing, staining
and scanning of chips were carried out according to stand-
ard protocols (Affymetrix, Santa Clara, CA).
Analysis of gene expression profiling data
Analysis of the gene expression data is described in detail
in Additional file 2 and as described previously [11,13].
Raw data for gene expression is provided in MIAME com-
plaint format in Array express, accession number E-MEXP-
1901
Table 1: Locally advanced rectal adenocarcinoma patients analysed by gene expression microarray.
Patient Treatment1 Stage at 
Diagnosis2
Diagnostic 
biopsy grade & 
histology
Diagnostic 
biopsy 
cellularity3
Surgical biopsy 
grade & 
histology
Surgical biopsy 
cellularity3
Pathological 
stage4
CRT1 CRT T2N1 M0 moderately 
differentiated 
adenocarcinoma
60% poorly 
differentiated 
adenocarcinoma
60% T3N2
CRT2 CRT T3N1 M0 moderately 
differentiated 
adenocarcinoma
60% moderately 
differentiated 
adenocarcinoma
60% T3N1
CRT3 CRT T3N0 M0 moderately 
differentiated 
adenocarcinoma
60% moderately 
differentiated 
adenocarcinoma
50% T3N0
CRT4 CRT T4N1 M0 moderately 
differentiated 
adenocarcinoma
50% moderately 
differentiated 
adenocarcinoma
50% T2N0
RT1 RT T2N0 M0 moderately 
differentiated 
adenocarcinoma
60% moderately 
differentiated 
adenocarcinoma
60% T3N0
RT2 RT T2N1 M0 moderately 
differentiated 
adenocarcinoma
60% moderately 
differentiated 
adenocarcinoma
60% T2N1
RT3 RT T2N0 M0 moderately 
differentiated 
adenocarcinoma
50% moderately 
differentiated 
adenocarcinoma
60% T3N2
RT4 RT T2N0 M0 moderately 
differentiated 
adenocarcinoma
60% moderately 
differentiated 
adenocarcinoma
60% T3N0
CON1 None T3N1 M0 moderately 
differentiated 
adenocarcinoma
75% moderately 
differentiated 
adenocarcinoma
70% T3N1
CON2 None T2N1 M0 moderately 
differentiated 
adenocarcinoma
50% moderately 
differentiated 
adenocarcinoma
50% T3N1
1 CRT = neoadjuvant concurrent chemoradiotherapy; RT = Short course pre-operative radiotherapy. 2 MRI and clinical stage. 3 % Tumour versus 
normal cells in biopsy profiled. 4 Pathological stage post-preoperative therapy
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Immunohistochemistry
Description of the Tissue Microarray (TMA) is provided in
previous publications [14]. A total of 268 colorectal
tumours and 50 normal colon cores are represented, with
1 core per case. During the staining procedure 34 (13%)
tumour cores were lost, leaving cores from 234 patients
available for assessment. Antigen retrieval was performed
by microwaving in 10 mM citrate (pH 6.0) for 20 minutes.
An autostainer (Dakocytomation, Glostrup, Denmark)
was used for staining the sections using a mouse mono-
clonal primary antibody for human APRIL/TNFSF13
(1:60 dilution, Abcam, Cambridge, UK) and Chemate-
Envision detection system (Dakocytomation, Glostrup,
Denmark), according to the manufacturer's instructions.
All sections were double scored by 2 independent investi-
gators who were blinded to the clinical data. Scoring dis-
crepancies were resolved by examination of sections at a
double-headed microscope. Sections were scored positive
or negative for tumour and/or stromal staining. In addi-
tion tumour staining intensity was scored as weak, mod-
erate or strong.
Statistical analysis
Continuity corrected χ2 test, with Fisher's exact test where
appropriate, was used for binary categorical variables,
Pearson's χ2 test for non-binary categorical variables and
Student's t-test for numerical variables. Kaplan-Meier
curves were constructed to assess survival and the log rank
test to assess statistical significance. The Cox proportional
hazards model was used for multivariate analysis of sur-
vival. Two-sided p values of less than 0.05 were considered
significant. All analyses were performed using SPSS for
Windows, version 13.0 (SPSS Inc, Chicago, IL).
Results
Chemo-radiotherapy or radiotherapy altered gene 
expression in rectal cancer
In a pilot transcriptomics study of rectal cancer patients,
we used oligonucleotide microarrays to profile the expres-
sion of over 47000 transcripts representing 38562 human
genes in rectal tumour biopsies before and after pre-oper-
ative treatment with CRT (n = 4 patients); table 1). Rectal
tumour biopsies before and after SCRT (n = 4 patients;
table 1) were also analysed to enable comparison of gene
expression changes in patients treated with 5FU-based
chemo-radiotherapy with those observed in patients
receiving radiotherapy alone. Rectal tumour biopsies, at
diagnosis and surgical resection, from two patients who
did not undergo any pre-operative treatment (table 1)
were used to identify treatment-independent gene expres-
sion changes.
SOPs were developed and validated to allow collection of
tissues at endoscopic diagnosis and at surgical resection,
whilst preserving RNA integrity. Total RNA extracted from
these tissues (10-30 mg) in this pilot study provided suffi-
cient yield (8 to 40 ug) and quality total RNA for gene
expression analysis on Affymetrix oligonucleotide micro-
arrays. Raw gene expression data is provided in MIAME
complaint format in Array express, accession number E-
MEXP-1901.
Threshold and probabilistic filtering of the data (see Addi-
tional file 2) identified 86 genes (91 probe sets) consist-
ently, significantly and specifically altered following 5FU-
based CRT and 51 genes (58 probe sets) following SCRT
(see Additional File 3 for details of genes and fold change
following therapy). Hierarchical cluster analysis, high-
lights 2 distinct clusters of genes up-regulated or down-
regulated following CRT (figure 1A) or SCRT (figure 1B).
The expression profiles of each of these gene sets clearly
separates pre- and post-treatment samples into two pri-
mary clusters for each treatment group (figure 1). A matrix
analysis (DMTv1.0, Affymetrix, CA) of therapy-altered
gene sets identified using threshold filtering alone (see
Additional file 2; 697 probe sets in CRT group and 570 in
SCRT group, including 86 overlapping), reveals that these
genes sets are significantly non-overlapping (p = 0.010),
demonstrating highly distinct alterations to the tumour
transcriptome following treatment with SCRT or 5FU-
based CRT.
The biological functions of the CRT and SCRT altered gene
sets were evaluated (additional file 4). While many of the
same key biological pathways are identified in each treat-
ment group, consistent with a co-ordinated transcrip-
Table 2: Resected colorectal adenocarcinoma patients analysed 
by immunohistochemistry for APRIL protein expression on 
tissue microarray
Variable Frequency/median(range)
Age 71 years (22-92)
Gender
Male 121
Female 113
Histological Grade
Poor 27
Moderate 199
Well 8
Tumour site
Proximal colon 79
Distal colon 86
Rectum 69
Stage
I 46
II 86
III (adjuvant chemotherapy)1 102 (63)
N2 48
1In this series 63/102 (62%) Stage III patients received adjuvant 
chemotherapy with 5FU
BMC Cancer 2009, 9:434 http://www.biomedcentral.com/1471-2407/9/434
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tional response, there are some pathways only altered
following CRT and some pathways (cell death and cell
cycle) where there is numerically significantly more
change in gene expression in the CRT treated patients
(additional file 4).
This represents an initial pilot study of the first samples in
our rectal cancer patient cohort. It is important to note
that the small sample size, necessitates validation of these
candidate gene expression changes in a larger cohort. The
primary aim of this study was to identify candidate 5FU
resistance markers in rectal tumours, in a pilot discovery
study using a transcriptome-wide approach and to vali-
date key candidate/s that may have mechanistic relevance
in a larger cohort. Identification and validation of one
such marker is described below.
APRIL/TNFSF13 in colorectal cancer
As we were interested in potential mediators of 5FU resist-
ance in rectal tumours in vivo, we further mined the gene
expression analysis using a pathway focussed analysis of
cell deaths pathways, including those involved in regula-
tion or execution of caspase-dependent apoptotic, cas-
pase-independent and necrotic cell death genes (n = 2177
genes; additional file 5). Threshold and probabilistic fil-
tering of the gene expression data identified 17 cell death
genes consistently and significantly altered in rectal
tumours following chemo-radiotherapy (additional file
6). Several of these genes have been implicated in colorec-
Hierarchical cluster analysis of chemoradiotherapy or radiotherapy treated tumoursFigure 1
Hierarchical cluster analysis of chemoradiotherapy or radiotherapy treated tumours. This analysis separates pre- 
and post-treatment biopsies using (a) 86 genes identified as changed in chemoradiotherapy treated patients and (b) 51 genes 
identified as changed in short course radiotherapy treated patients. (c) Post-treatment tumour biopsies, cluster according to 
treatment received with the combined set of 137 genes, but (d) pre-treatment tumour biopsies do not. Columns represent 
tumour samples and rows represent genes (red: up-regulated and green: down-regulated, radiotherapy [blue] or chemoradio-
therapy [pink]).
(b)(a)
(d)(c)
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tal cancer pathogenesis and the pathogenesis of other can-
cers, and also radioresistance, but none previously in 5FU
chemoresistance (for more details see additional file 6).
Comparison of the 17 cell death genes altered in response
to 5FU based CRT in tumours from rectal cancer patients,
with gene expression changes identified in our previous
study of 5FU resistant cancer cell lines [11], demonstrated
4 of the 17 genes up-regulated following CRT (but not
radiotherapy alone) in rectal cancer patients and in 5FU-
resistant cancer cells compared to the sensitive parental
lines(See additional file 6, Table S6.1). This included the
TNF superfamily ligand, APRIL (TNFSF13).
APRIL has been characterised as promoting cell survival
and cell proliferation and this involves NFκB activation
[15-19]. In addition, APRIL mRNA has been shown to be
increased in colorectal tumours compared to normal
mucosa [17]. These data supported further investigation
of a putative functional role for APRIL in clinical 5FU
chemo-resistance.
APRIL protein expression was evaluated in 234 resected
colorectal adenocarcinomas and 50 normal colon or rec-
tal mucosa specimens (table 2). APRIL protein was not
expressed in normal colon tissues but was, as expected,
expressed in both colorectal tumour cells and the tumour
stroma (Table 3 and figure 2). Tumour cell staining was
observed in the cytosol and membrane of tumour cells
(figure 2). Stromal staining was evident in both the extra-
cellular matrix and also in stromal cells (figure 2).
APRIL, a putative 5FU chemo-resistance factor and 
predictive biomarkerin 5FU treated colorectal cancer 
patients
We examined the relationship between APRIL protein
expression and survival after surgical resection. We pro-
spectively determined that we would evaluate both
tumour cell and tumour stromal expression of APRIL pro-
tein due to its characterized biological function as a
secreted autocrine and/or paracrine molecule. There was
no significant relationship between APRIL protein expres-
sion in tumour cells and survival (Additional file 7). In
contrast, expression of APRIL protein in the tumour
stroma was associated with poor survival (n = 234, p =
0.019, figure 3a), including in stage III patients (n = 102,
p = 0.016, figure 3b), but was not associated with survival
in Stage I or II (n = 46 p = 0.601 and n = 86 p = 0.440,
respectively, Additional File 7).
In light of our hypothesised role of APRIL in 5FU resist-
ance, we stratified the Stage III patients according to
whether or not they received adjuvant chemotherapy with
5FU following surgical resection of their primary tumour.
Stage I and II patients did not receive adjuvant chemother-
apy in this series. Tumour stroma expression of APRIL
protein is only associated with worse survival in those
patients treated with adjuvant 5FU and there is no rela-
tionship with survival in Stage III patients not treated with
adjuvant chemotherapy (n = 102, p < 0.001, figure 3c). In
5FU treated Stage III patients (n = 63), median survival for
stroma positive is 36 months with predicted 5 year sur-
vival 42.0% (95% confidence interval 11.8% - 72.2%);
median survival not yet reached for stroma negative and
predicted 5 year survival is 85% (95% confidence inter-
vals 71.7%-98.6%). Multivariate analysis confirms expres-
sion of APRIL protein in the tumour stroma as an
independent prognostic factor in chemotherapy treated
Stage III patients, with a HR of 6.25 (95% CI 1.48-26.32,
p = 0.013, table 4).
The survival of the 5FU treated Stage III colorectal cancer
patients who express APRIL protein in the tumour stroma
parallels survival observed in Stage III patients who did
not receive adjuvant therapy (treatment decision due to
patient or physician preference), irrespective of APRIL
protein expression (figure 3c). In contrast, the APRIL neg-
ative patients have an excellent predicted 5 year survival
and have a clear and statistically significant (p < 0.001)
survival benefit compared to untreated or APRIL positive
5FU treated patients (figure 3c). These data suggest that
APRIL has no prognostic impact in colorectal cancer
treated by surgical resection alone, but has predictive
impact for benefit from adjuvant 5FU in colorectal cancer
patients.
Discussion
Global gene expression profiling of clinical response to
therapy has provided a useful means for biomarker and
novel target discovery in several solid tumours [5,13]. The
Table 3: Tumour cell and stromal expression of APRIL protein in 
colorectal adenocarcinomas.
APRIL Immunohistochemistry
Tumour Cell Positive 130 (55.6%)
Weak 70 (29.9%)
Moderate 49 (20.9%)
Strong 11 (4.7%)
Stroma Negative 104 (44.4%)
Positive 121 (51.7%)
Negative 113 (48.3%)
Immunohistochemical analysis of a rectal adenocarcinoma tissue 
microarray (n = 234 tumours) demonstrated that APRIL protein was 
expressed in tumour cells and/or tumour stroma. Positive stromal 
expression was strong. In tumour cells expressing APRIL, intensity 
was weak, moderate or strong. The number of rectal 
adenocarcinomas with positive staining for APRIL protein. Percentage 
of the total (n = 234) is in parentheses. There was a significant 
correlation between tumour cell and stromal expression (p = 0.048). 
There was no significant association between tumour cell or stromal 
staining and age, gender, histological grade, tumour site or Duke's 
stage (all p > 0.20. Data not shown).
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work described in this paper has used and extended this
experimental approach to rectal adenocarcinomas. The
data presented constitutes an analysis from gene expres-
sion profiling of prospectively collected pre- and post-
treatment tumour specimens from patients with rectal
adenocarcinomas receiving pre-operative therapy.
Since a small number of rectal adenocarcinomas have
been profiled (n = 10), stringent and focussed analysis of
the microarray data was applied to identify leads for fur-
ther investigation. This included hypothesis-driven focus
on cell death pathways and comparison with our previ-
ously published cell line work. The key candidate was sub-
sequently validated a in larger independent set (n = 234)
using a different technique (immunohistochemistry).
The biological validity of the experimental model and the
data is confirmed by the finding of significant alterations
in the gene expression of previously implicated molecules
and pathways, for example p21 which has been impli-
cated in numerous studies [20-25]. The biological path-
ways identified (information 3 and 4) suggest a co-
ordinated transcriptional response to radiotherapy- and
CRT- induced cellular stress, consistent with other reports
involving gene expression profiling in cell lines and sev-
eral different cancer types [2,11,13,25-29]. We hypothe-
size that this reflects distinct biological effects of these two
treatments. However, the possibility of effects due to time
course differences in the tumour sampling in each group
cannot be excluded.
A supervised analysis of cell death genes, reveals shared
genes and pathways. The analysis supports the hypothe-
sise that initiation of cell death is a common final path-
way resulting from a multitude of upstream responses to
the insult and resultant cellular stress of cytotoxic chemo-
therapy or radiotherapy thereby accounting for gene
expression overlap seen.
The majority of the genes identified in our analysis repre-
sent genes and pathways that have not previously been
implicated in clinical response of rectal adenocarcinoma
or as mechanisms of action or resistance to radiotherapy
or 5FU or 5FU-based CRT. This is consistent with the find-
ings of other gene expression profiling studies in rectal
adenocarcinoma or other tumour types for radiotherapy
or 5FU [6,8-11,26,28-30]. However, it is important to
note that this discovery phase utilised a small sample
cohort and the candidate gene expression changes require
further validation in a lrger independent cohort.
APRIL/TNFSF13 was found to be upregulated following
CRT but not radiotherapy alone in rectal cancers and was
also up-regulated in 5FU resistant cell lines in our previ-
Immunohistochemistry for APRIL in resected colorectal adenocarcinomasFigure 2
Immunohistochemistry for APRIL in resected colorectal adenocarcinomas. Staining for APRIL was seen in the 
tumour cells (membrane and cytosol) and stroma (extracellular matrix and stromal cells) of colorectal adenocarcinomas. All 
combinations of tumour cell and stromal staining were seen. Tumour cell staining could be scored weak, moderate and strong. 
Examples show strong tumour cell staining and stromal staining.
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ous studies [11]. The biological function of APRIL as a
secreted molecule that has autocrine and paracrine func-
tions to promote cell survival and proliferation and its
previously documented expression in colorectal adeno-
carcinoma but not normal cells outside the immune sys-
tem, supported it's further investigation as a novel
mechanism of 5FU action and resistance, and as a predic-
tive biomarker [15-19,31-35].
This study found that expression of APRIL protein in
colorectal tumour stroma was associated with worse sur-
vival, but only in those patient's treated with adjuvant
5FU chemotherapy. This relationship was also main-
tained in a multivariate analysis of 5FU chemotherapy
treated Stage III colorectal adenocarcinoma patients (HR
6.25, 1.47-26.31, p = 0.013), in which the Hazard ratio
compares favourably to other previously published puta-
tive 5FU predictive biomarkers in colorectal cancer [2-4].
Tumour cell expression of APRIL was correlated with stro-
mal staining but was not significantly associated with sur-
vival. Overall, APRIL appears to have no therapy
independent prognostic impact in colorectal adenocarci-
noma in this analysis.
APRIL protein expression in tumour stroma and survival of colorectal cancer patientsFigure 3
APRIL protein expression in tumour stroma and survival of colorectal cancer patients. (a). Kaplan-Meier survival 
plots for tumour stroma APRIL protein expression analysed by immunohistochemistry of 234 colorectal cancer patients fol-
lowing surgical resection.(b) Stromal staining for APRIL in Stage III patients following surgical resection (n = 102) (c) Combined 
analysis of stage III patients (n = 102) stratified according to adjuvant therapy and tumour stroma APRIL protein. P value is log 
rank test.
p=0.019
Negative
Positive
a b
Negative
Positive
p=0.016
c
p<0.001
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Within the limitations of a retrospective study, these
results suggest that APRIL may have clinical utility as a
predictive biomarker to select patients who would not
benefit from adjuvant 5FU monotherapy. For example,
currently adjuvant 5FU is used clinically in an empirical
way without predictive biomarkers in stage III patients
and in this paradigm the majority of patients with Stage III
cancers will not benefit from 5FU. Therefore, the ability to
identify some of these stage III patients who will not ben-
efit from 5FU has clear potential clinical utility in optimis-
ing and individualising clinical use of 5FU in this setting.
An important question is whether APRIL confers cross
resistance to other active agents used to treat colorectal
cancer, especially Oxaliplatin and Irinotecan, this would
be potentially useful to guide 5FU combination adjuvant
therapy in stage III patients, but especially in stage II
patients where 5FU alone appears to have limited benefit.
The data allows us to hypothesise that APRIL may provide
a useful novel therapeutic target. Morphological examina-
tion has suggested that positively staining stromal cells
include lymphocytes and fibroblasts, but not endothelial
cells. This is consistent with evidence indicating that
APRIL is predominantly secreted and exerts it's effects via
cell surface receptors, acting in a paracrine or autocrine
fashion [15-19,31-35].
Our data indicate that APRIL might be secreted by tumour
cells or stromal cells within the tumour. The APRIL signal-
ling mechanisms that may mediate tumour cell survival
are not well characterised [32]. However, in vitro work in
glioma cell lines and ex vivo studies in BCLL, has shown
that APRIL stimulates proliferation and inhibits apoptosis
in response to a wide range of stimuli, including CD95L,
TRAIL and cytotoxic drugs and survival in B-CLL cells
involves NFκB activation [15-19,31-34]. More recently it
has been suggested that tumour infiltrating neutrophils
may be an important source of APRIL production in solid
tumours [35].
If APRIL is functional as an extracellular secreted molecule
this makes it amenable to targeting with either a small
molecule inhibitor or monoclonal antibody, as has been
employed successfully for other targets in solid tumours
e.g. bevacizumab against VEGF. An anti-APRIL targeted
therapy may be useful in reversal of acquired 5FU resist-
ance or in combination in patients whose tumours over-
express the molecule.
The lack of therapy independent prognostic impact sug-
gests that an anti-APRIL therapy may not have anticancer
activity on it's own, but the cell survivalpromoting activity
may be more generally applicable to other therapeutic cell
death stresses. Therefore, combination of an anti-APRIL
agent with agents other than 5FU may be active, and our
cell line data also suggest that they may be active in other
tumour types, such as breast cancer.
Conclusions
In this study we have used a combined investigative
model, analysing the transcriptional response in clinical
tumour specimens from rectal adenocarcinomas and can-
cer cell lines, to identify APRIL, as a novel 5FU chemo-
resistance biomarker. We have validated its importance in
an independent set of colorectal adenocarcinomas. This
data supports further investigation of the clinical utility of
APRIL as a predictive biomarker for 5FU resistance in
colorectal adenocarcinomas and other solid tumour types
and also as a target for novel therapeutics aimed at
reversal of clinical resistance to 5FU and its oral ana-
logues.
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